[Cardiologic sequelae of cytostatic therapy]

As more and more oncologic patients are being cured from cancer, problems with long-term cytostatic cardiologic complications have triggered and intensive investigation. Cardiotoxicity becomes a specific problem for those who survived cancer therapy with anthracycline. Heart failure or ventricular arrhythmias may develop from subclinical myocardial alterations induced by anthracycline therapy. Long-lasting monitoring of cardiac status may help to identify those patients, whose abnormalities have progressive character and who are at risk of fatal complications.